MannKind Corporation to Participate in H.C. Wainwright Global Life Sciences Conference
MannKind Corporation (Nasdaq: MNKD) announced that CEO Michael Castagna will present at the H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
MannKind Corporation (Nasdaq: MNKD) announced that CEO Michael Castagna will present at the H.C. Wainwright Global Life Sciences Conference. The presentation will be available on demand starting March 9, 2021, at 7:00 am (ET). Interested viewers can access the webcast link from the Events & Presentations section of MannKind's website. The replay will be available for 14 days after the live event. MannKind focuses on inhaled therapeutic products, including the FDA-approved Afrezza®, an ultra-rapid-acting mealtime insulin available by prescription in the U.S. and Brazil.
Details
News Market Reaction – MNKD
The recorded move for MNKD in the trading session of this news was -4.23%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WESTLAKE VILLAGE, Calif., March 02, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that its Chief Executive Officer, Michael Castagna, PharmD, will present at the H.C. Wainwright Global Life Sciences Conference which will be available on demand starting on March 9, 2021 at 7:00 am (ET). Interested parties can access a link to the on demand webcast of the presentation from the Events & Presentations section of the Company's website at http://www.mannkindcorp.com. The webcast replay will remain available for 14 days following the live presentation.
About MannKind Corporation
MannKind Corporation (Nasdaq: MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases. MannKind is currently commercializing Afrezza® (insulin human) Inhalation Powder, the Company’s first FDA-approved product and the only inhaled ultra rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide. Afrezza is also available by prescription in Brazil where it is commercialized by the Company’s partner Biomm SA. MannKind is headquartered in Westlake Village, California, and has a state-of-the-art manufacturing facility in Danbury, Connecticut. The Company also employs field sales and medical representatives across the U.S. For further information, visit www.mannkindcorp.com.
Company Contact:
818-661-5000
ir@mannkindcorp.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.